アルツハイマー病の臨床サブタイプによるアミロイドβ線維の構造的変化
Wei Qiang1, Wai-Ming Yau1, Jun-Xia Lu1
1Laboratory of Chemical Physics, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.
Nature
|January 5, 2017
まとめ
アルツハイマー病のアミロイドβ線維の構造は,臨床的サブタイプによって異なります. 特定のアミロイド-β40繊維構造は典型的およびPCA形態と関連しているが,急速に進行する形態は構造的な多様性を示している.
科学分野:
- 神経科学
- 生物化学
- 構造生物学
背景:
- アミロイド-β (Aβ) ペプチドが繊維に結合することは,アルツハイマー病 (AD) の病原性の鍵です.
- Aβ繊維の構造は多形であり,プリオン菌株に類似したADの臨床表型と相関することがあります.
研究 の 目的:
- アミロイドβ線維の構造的変異とアルツハイマー病の異なった表型との相関を調査する.
- 典型的なAD (t-AD),急速に進行するAD (r-AD),後部皮質縮AD (PCA-AD) のAβ線維構造を比較する.
主な方法:
- 固体核磁気共振 (ssNMR) を用いてAβ40とAβ42の繊維構造を分析した.
- 繊維はアルツハイマー病の脳皮質の抽出物から育った種で作られました.
- 異なるADサブタイプを代表する18人の37人の皮質組織サンプルを分析した.
主要な成果:
- t-ADとPCA-ADのサンプルでは,単一のAβ40フィブリル構造が優勢であった.
- r-ADサンプルからのAβ40線維は,追加構造の割合が大きいことを示した.
- Aβ42線維は,すべての患者カテゴリーで構造的異質性を示し,少なくとも2つの構造が一般的であった.
結論:
- 特定のAβ40繊維構造が典型的およびPCA-ADに関連しています.
- 急激に進行するADは,追加のアミロイドβ線維構造を含む可能性があります.
- アルツハイマー病の脳組織におけるAβ40とAβ42の集合体には質的差異がある.
さらに関連する動画
09:31Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry
Published on: March 7, 2019
11.2K
14:55Atomic Scale Structural Studies of Macromolecular Assemblies by Solid-state Nuclear Magnetic Resonance Spectroscopy
Published on: September 17, 2017
16.1K
関連する概念動画
03:03Amyloid Fibrils
12.4K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
12.4K
03:03Amyloid Fibrils
6.8K
6.8K
01:26Alzheimer's Disease: Overview
1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
01:22Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K